Brain Cancer

NCCN Clinical Practice Guidelines in Oncology: 2020 UpdatesBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

Go to full news story published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Intraoperative MRI Versus 5-ALA in High-Grade Glioma Resection: A Network Meta-AnalysisBookmark

Research paper from the Journal of Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

The extent of tumor resection—how much of the tumor is able to be removed—at the initial surgery is probably the most important factor in prognosis of glioblastoma. This academic research paper explores methods that help surgeons maximize tumor removal.

Go to full paper published in the Journal of Neurosurgery.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

A Systematic Review of Tumor Treating Fields Therapy for High-Grade GliomasBookmark

Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

Go to full paper published in Journal of Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant GliomaBookmark

Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.

The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent GlioblastomaBookmark

Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

The Central Nervous System Tumor Methylation Classifier Changes Neuro-Oncology Practice for Challenging Brain Tumor Diagnoses and Directly Impacts Patient CareBookmark

Academic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes: 

Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.

Go to full academic research paper from Clinical Epigenetics.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Brain Tumor Liquid Biopsy Detects DNA Methylation ProfilesBookmark

Article from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes: 

Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.

Go to full article published by Clinical OMICs.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Predicting Prognosis in GlioblastomaBookmark

Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes: 

Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).

Go to full article published by The Pathologist.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Diagnostic Testing for Diffuse GliomasBookmark

Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

Go to full announcement published by the College of American Pathologists.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Researchers Tap Genomic Technology to Develop Personalized Treatments for Pediatric GliomaBookmark

Excerpt:

“Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

“Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”

Go to full article published by Healio on Feb 3, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ATIM-14. Results of Phase II Clinical Trial of Oncolytic Herpes Virus G47∆ in Patients with GlioblastomaBookmark

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Is Polio the Answer to Curing Brain Tumors?Bookmark

Article from WKYC Studios curated by Editor in Chief George Lundberg, MD, who notes: 

An experimental treatment in which the virus that causes polio is directly injected into glioblastoma (GBM) tissue has shown some promise, as reported in the New England Journal of Medicine in 2018. This news story from WKYC provides a partial update from an ongoing subsequent clinical trial.

Go to full article published by WKYC Studios.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)Bookmark

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

These clinical trial results suggest that six cycles of temozolomide is as effective as 12 for patients with glioblastoma and produces fewer side effects.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Bevacizumab and Temozolomide in First Recurrence of Glioma Without 1p/19q CodeletionBookmark

Excerpt from The ASCO Post:

“In a phase II trial funded by the European Organisation for Research and Treatment of Cancer and reported in The Lancet Oncology, van den Bent et al found no evidence of a survival benefit with the addition of bevacizumab (Avastin) to temozolomide in patients with a first recurrence of World Health Organization grade II or III glioma without the 1p/19q codeletion.

“In the open-label trial, conducted at 32 European centers, 155 patients were randomized between February 2011 and July 2015 to receive either temozolomide at 150 to 200 mg/m² on days 1 to 5 every 4 weeks for a maximum of 12 cycles (n = 77) or the same temozolomide regimen plus bevacizumab at 10 mg/kg every 2 weeks until disease progression (n = 78). Previous chemotherapy must have been stopped at least 6 months before enrollment, and radiotherapy, at least 3 months before enrollment. Overall, 44% of patients in the combination group and 47% in the temozolomide group had grade III disease.”

Go to full article published by The ASCO Post on Aug 20, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

First Patient Dosed in Phase I/II Trial of Novel Immunotherapy Combination in Newly Diagnosed GlioblastomaBookmark

Excerpt from Targeted Oncology:

“The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma (GBM). Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.

“This study aims to investigate the efficacy of INO-5401, a T-cell activating immunotherapy agent encoding multiple antigens in GBM, and INO-9012, an immune activator encoding IL-12, in combination with the PD-1 inhibitor cemiplimab (REGN2810).”

Go to full article published by Targeted Oncology on July 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pediatric Cancer: The “Day One Talk”Bookmark

Article from the Journal of Clinical Oncology, curated by Cancer Commons founder Marty Tenenbaum, PhD.

This piece discusses a “method of delivering bad news to parents of children with cancer in hopes that our approach may be helpful to others and may spur discussion.”

.

Global Post-Marketing Safety Surveillance of Tumor Treating Fields (TTFields) in Patients With High-Grade Glioma in Clinical PracticeBookmark

Research paper from the Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Safety and potential adverse effects are serious issues with many cancer treatments. This academic paper outlines post-marketing research that reveals few adverse effects from a type of treatment known as tumor-treating fields (TTF) in brain malignancies.

Go to full paper published in the Journal of Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic DiseaseBookmark

Research paper from Cancers curated by Editor in Chief George Lundberg, MD, who notes: 

Instead of focusing on “curing” cancer, the authors of this academic research paper focus on approaches to managing cancer as a chronic disease.

Go to full paper published in Cancers.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Trials Gone VirtualBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

These Underlying Conditions Make Coronavirus More Severe, and They’re Surprisingly CommonBookmark

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.